In a bold move to broaden its interests overseas, Japanese drugmaker Sumitomo Dainippon (TYO: 4506) has agreed to pay $3 billion for a chunk of Roivant Sciences’ biopharmaceutical units, plus a 10% share in the rest of the company.
The deal will involve the creation of a novel and broad Alliance to include the transfer of Roivant’s ownership interests in five of its biopharmaceutical companies, with an option to acquire up to six more.
The agreement also provides access to Roivant’s proprietary technology platforms, DrugOme and Digital Innovation, and Sumitomo will take a 10% stake in the rest of Roivant.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze